Abstract
Corticosteroids such as dexamethasone (DEX) increase leucine turnover and oxidation in humans and animals, indicating whole body protein catabolism. Recently, interest has been growing in the use of recombinant polypeptides such as GH and IGF-I in reversing various states of catabolism. The aim of our study was to investigate whether IGF-I reverses corticosteroid-induced protein catabolism in rapidly growing piglets. Also, we wanted to determine whether IGF-I attenuates corticosteroid-induced hyperglycemia. To study these questions, we performed leucine kinetic studies and measured blood glucose in eight piglets under postabsorptive conditions. We did three studies in each piglet: baseline, DEX treatment (5 mg/kg/d for 4 d), and DEX plus IGF-I treatment (25 μg/kg/h for 6 h). DEX increased leucine turnover by 18± 14% (mean ± SD, p < 0.05), and oxidation by 132± 64% (p < 0.01) over baseline values. Adding IGF-I to DEX treatment failed to reverse these changes in leucine kinetics. Turnover again increased by 18 ± 8% (p < 0.01), and oxidation by 107± 68% (p < 0.05) over baseline values. Nonoxidative leucine disposal, an indicator for protein synthesis, did not significantly differ after treatment with DEX or with DEX. plus IGF-I. Blood glucose values increased over baseline values after DEX treatment, and approached baseline values after DEX plus IGF-I. We conclude that IGF-I attenuates corticosteroid-induced hyperglycemia, but does not reverse corticosteroid-induced protein catabolism in growing piglets.
Similar content being viewed by others
Main
The deleterious effects of corticosteroids on growth have been known for a long time(1) and are a continuing cause for concern in pediatric patients. High plasma levels of corticosteroids increase leucine turnover and oxidation, indicating whole body protein catabolism, in human adult volunteers(2, 3) and in infants with bronchopulmonary dysplasia(4). Plasma amino acid levels are increased in infants under corticosteroid treatment(5). This is in part due to increased breakdown of muscle protein(6). Recently, there has been increasing interest in the use of recombinant polypeptide growth factors (GH, IGF-I, and IGF-I analogs/derivatives) to reverse various states of catabolism, among which is corticosteroid-induced protein catabolism. As early as 1952, Selye(7) demonstrated improved growth in glucocorticoid-treated rats if bovine GH was administered. A reversal of protein catabolism by increased protein synthesis has been proposed as mechanism for the anabolic actions of GH in corticosteroid-treated adults(8). Administration of IGF-I improves nitrogen balance in fasted lambs(9), and decreases whole-body leucine turnover in healthy human volunteers, suggesting decreased protein breakdown(10). We used DEX-treated rapidly growing piglets as an animal model for corticosteroid-induced protein catabolism in pediatric patients. Piglets were chosen for this model, because DEX treatment produced changes in leucine kinetics in piglets (our own data) similar to those reported in humans(2–4), and because the porcine GH/IGF-axis is similar to that in man-the porcine IGF-peptide is identical to human IGF-I(11). IGF-I was chosen as a possible antagonist for corticosteroid-induced protein catabolism in our study because it mediates GH action(12), interacts readily with the insulin receptor to lower glucose levels(13), and could thus be expected to attenuate corticosteroid-induced glucose intolerance. Our goal was to determine whether IGF-I reverses corticosteroid-induced protein catabolism in growing piglets, and whether IGF-I attenuates corticosteroid-induced hyperglycemia.
METHODS
Study design. We did three experiments on each piglet, at weekly intervals: baseline, DEX treatment, and DEX and IGF-I treatment combined, the latter two studies being carried out in a crossover study design. On study days, the piglets were sedated by intramuscular administration of 40 mg of azaperone (Stresnil®, Janssen Pharmaceutica BV, Tilburg, The Netherlands) and 5 mg of diazepam (t = 0 min). Azaperone is a butyrophenone neurolepticum which reduces stress-related increases in muscle glycolysis in pigs(14), diazepam is a benzodiazepine anxiolyticum which reduces stress effects on the autonomic nervous system(15). Piglets were then placed in hammocks(t = 15 min), and 40 mg of azaperone and 5 mg of diazepam were administered hourly during the course of the experiment. On the baseline study day (wk 1), i.v. tracers were administered to the piglets. Preceding study days in wk 2 and 3, piglets were treated with DEX, administered i.v., at a dose of 5 mg/kg, for 3 d, and also on the study day, 3 h before sedation(t = -180 min). Food intake was not affected by DEX treatment. On the study day in wk 2, one half of the piglets (n = 4), additionally received a primed, constant rate infusion of IGF-I (provided by Genentech Co., South San Francisco, CA). IGF-I was diluted in 0.9% sterile saline solution to a concentration of 100 μg/mL. Prime dose was 25 μg/kg (starting att = 30 min), followed by constant rate infusion of 25 μg/kg/h during the remainder of the experiment (t = 40 min until t= 370 min). On the study day in wk 3, the effect of DEX was determined. The other half of the piglets (n = 4) received IGF-I on the study day in wk 3, using the same regimen, after determination of the effect of DEX on the study day in wk 2. The crossover design was chosen to control for a possible influence of the total duration of DEX treatment on leucine kinetic parameters.
Exclusion criteria. Animals in which it was not possible to complete all three experiments were excluded from the study. Two piglets were excluded due to catheter obstruction before the final experiment, and one piglet due to infection.
Animals. Eight female crossbred (Landrace × Yorkshire) piglets, with an average weight of 12.5 kg (10.0-15.3 kg) on the first study day, were used for the study. Piglets were fed 50 g/kg/d of a standard diet containing 17.4 wt% protein (Hendrix B.V., Boxmeer, The Netherlands). Average weekly weight gain was 1.5 ± 0.5 kg between study days in wk 1 and wk 2, and 1.7 ± 0.7 kg between study days in wk 2 and wk 3. After an acclimatization period of 1 wk, piglets were placed under general anesthesia, and catheters (8 ch Argyle®, Sherwood Medical, Tullamore, Ireland) were placed in the right carotid artery and jugular vein, then tunneled to the back of the neck s.c. Catheters were filled with 0.9% saline solution containing 2500 U/mL heparin. Piglets were fitted with jackets to protect the catheters from unwanted removal. Hereafter, piglets were housed separately. The first experiment in each piglet was carried out 1 wk after catheter placement. Piglets were terminated after the third experiment by injection of 1 g of pentobarbital sodium. The experiment protocol was approved by the Animal Ethics Committee of the University of Groningen.
Tracer administration (see also Fig. 1). 13C-Labeled bicarbonate (99% MPE) and[L-1-13C]leucine (99% MPE) were obtained from Tracer Technologies, Inc.(Somerville, MA). Tracers were dissolved in sterile 0.9% saline solution and sterilized by filtration through a 0.22-μm filter (Millipore GMBH, Eschborn, Germany) by the hospital pharmacy. 13C-Labeled bicarbonate was administered by primed, steady-state infusion through the venous catheter(prime dose 7 μmol/kg, starting at t = 50 min, followed by infusion at a rate of 5 μmol/kg/h for 2 h, starting at t = 60 min). After 2 h, bicarbonate infusion was stopped, and 13C-labeled leucine was infused (prime dose 15 μmol/kg, starting at t = 180 min, followed by infusion at a rate of 15 μmol/kg/h for 3 h, starting att = 190 min). Tracers were administered via a calibrated infusion pump (model CS03E, MGVG, Munich, Germany).
Measurement of [13C]bicarbonate enrichment in arterial blood. To measure leucine oxidation, subsequent infusion of labeled bicarbonate and leucine were used, as described by Goudoever et al.(4, 16). We modified their protocol by measuring13 C-enrichment in plasma bicarbonate rather than in expired CO2. It has previously been demonstrated that 13C-enrichment in bicarbonate is equivalent to that in expired CO2 in human adults(17). To validate this assumption for our piglet model, we conducted three separate experiments in one ventilated piglet under inhalation anesthesia, using the same infusion protocol described above. During these experiments, we simultaneously collected samples of arterial blood and of expired gas to compare 13C-enrichments.13 C-Enrichment in arterial blood bicarbonate was determined as described below. For the determination of 13C-enrichment in expired CO2, 20 mL of gas were collected from the expiratory end of the ventilator, and stored in 20-mL vacuum containers (Vacutainer®, Becton Dickinson, Grenoble, France) at room temperature until analysis. A 100-μL sample of this gas was with-drawn and analyzed for 13CO2 enrichment with a Delta S isotope-ratio mass spectrometer (Finnigan MAT, Bremen, Germany). Enrichments in bicarbonate and in expired CO2 did not significantly differ from each other, the ratio of bicarbonate enrichment to that of expired CO2 was 0.97 ± 0.03 (mean ± SD,n = 26). We therefore considered it valid to measure13 C-enrichments in blood bicarbonate rather than in expired CO2.
Blood samples were taken at t = 15 and 45 min (baseline samples); at t = 90, 120, 150, and 180 min (bicarbonate plateau samples); and at t = 235, 280, 310, 340, and 370 min (leucine plateau samples), for the determination of 13C-enrichment in blood bicarbonate. Whole blood samples (2 mL) were collected via the arterial catheter, and placed in 20-mL vacuum containers (Vacutainer®, Becton Dickinson, Grenoble, France), then stored at -80°C until analyzed. Blood samples were prepared for analysis as follows: after thawing the samples in the closed vacuum containers, 1 mL of 0.2 M lactic acid was added by syringe and the sample was vortexed to quantitatively liberate CO2 from blood bicarbonate. From the headspace above the blood sample, 20 μL of gas were withdrawn and analyzed for 13CO2 enrichment with a Delta S isotope-ratio mass spectrometer (Finnigan MAT, Bremen, Germany). The coefficient of variation for measurements of [13C]bicarbonate enrichment was 5% at an enrichment of 0.005 MPE (n = 10), and 1.5% at an enrichment of 0.020 MPE(n = 10).
Measurement of [13C]KIC enrichment in plasma. To determine leucine kinetics, [13C]KIC enrichment was measured, because plasma KIC better reflects intracellular leucine enrichment than plasma leucine, and is the intracellular precursor for protein synthesis and decarboxylation(18). Blood samples were taken att = 15 and 150 min, (baseline), and at t = 235, 280, 310, 340, and 370 min for determination of [13C]KIC enrichment during[13C]leucine infusion. Heparinized blood was centrifuged immediately and plasma was stored at -80°C until derivatization. Derivatization was carried out as follows. After thawing, 150 μL of plasma were deproteinized by addition of 2.5 mL of pure ethanol and subsequent centrifugation. The supernatant was evaporated to dryness under a stream of N2 at 50°C. Then 300 μL of 1% 1,2-phenylenediamine, dissolved in 2 M hydrochloric acid, were added, and the solution was heated to 90°C for 60 min, then allowed to cool. Extraction was carried out using 3 mL of ethyl acetate, and the organic phase was evaporated to dryness under a stream of N2 at 40°C. At 15 min before analysis, 50 μL ofN,O-bis(trimethylsilyl)-trifluoroacetimide was added.[13C]KIC isotopic enrichment was measured with a model HP5995 gas chromatograph/mass spectrometer system (Hewlett-Packard Co., Palo Alto, CA). Gas chromatography was carried out on a 20 m × 0.18 mm capillary column(DB-1701, J&W Scientific, Folsom, CA). Selective ion monitoring was carried out at mass/ionic charge number (m/z) 232 for (m) and 233 for (m + 1). Plasma [13C]KIC enrichments were determined by using a calibration graph obtained by measuring weighed mixtures containing 0 to 10% MPE [13C]KIC. The coefficient of variation for determination of [13C]KIC was 3.5% (n = 10).
Blood glucose. Blood glucose was determined at t = 15, 120, 235, and 370 min, at our clinical laboratory, by a glucose analyzer based on the glucose oxidase method (Yellow Spring Inc., Yellow Springs, OH).
IGF-I. Blood samples for determination of total serum IGF-I was taken at t = 15 and at t = 370 min in all experiments, and additionally at t = 120 and at t = 235 min during IGF-I infusion. IGF-I levels were determined by specific RIA(19), after acid-ethanol extraction(20), at the Endocrinological Laboratory of the Wilhelmina Children's Hospital, University of Utrecht, The Netherlands.
Calculations. Leucine turnover was calculated according to the formula:
Leucine oxidation was calculated according to Goudoever et al.(4): Equation
Nonoxidative leucine disposal was calculated by subtracting oxidation from turnover.
Statistical analysis. Data were analyzed using repeated measures analysis of variance. When significant differences were found, comparisons were completed by t test using the Bonferroni adjustment.
RESULTS
Leucine kinetic data. Mean [13C]bicarbonate enrichments are shown in Fig. 2, mean [13C]KIC enrichments inFig. 3. The calculated leucine kinetic data are summarized in Table 1. Leucine turnover increased after DEX treatment by 18 ± 14%, compared with baseline values (p < 0.05), and also under treatment with DEX plus IGF-I versus baseline (plus 18± 8%, p < 0.01). The difference in turnover between DEX and DEX plus IGF-I was not significant. Leucine oxidation was also higher under DEX treatment by 132 ± 64% versus baseline conditions(p < 0.01), and under DEX plus IGF-I versus baseline(plus 107 ± 68%, p < 0.05). Oxidation after DEX did not significantly differ from that after DEX plus IGF-I. Non-oxidative leucine disposal was not significantly different under DEX versus baseline, DEX plus IGF-I versus baseline, or DEX versus DEX plus IGF-I.
Blood glucose values (Fig. 4). Blood glucose values were higher throughout under DEX treatment when compared with the baseline study. Glucose levels before starting IGF-I infusions on DEX plus IGF-I study days were similar to DEX values, but significantly lower than under DEX during infusion of IGF-I. At t = 120 and 370 min, glucose values did not significantly differ between DEX plus IGF treatment and baseline conditions.
IGF-I values (Fig. 5). Serum IGF-I levels at the start of the experiment were not significantly different between treatment groups. In the DEX plus IGF-I group, IGF-I levels after starting IGF-I infusion increased rapidly. In the baseline experiments, IGF-I levels were slightly higher at t = 370 min when compared with the onset of the experiment.
DISCUSSION
Our study shows that IGF-I does not reverse corticosteroid-induced protein catabolism in growing piglets. To investigate corticosteroid-induced protein catabolism, we treated piglets with the corticosteroid DEX and used[13C]leucine kinetics to measure protein metabolism. In a dose-finding study (data not shown), DEX, at a dose of 5 mg/kg/h, administered for 4 d, was found to produce changes in leucine kinetics in piglets similar to those reported in corticosteroid-treated human adults(2) and infants(4). In our study, DEX increased leucine turnover and oxidation, indicating whole body protein catabolism. Adding IGF-I to DEX treatment failed to reverse these changes in leucine kinetics.
There are several possible explanations for the failure of IGF-I to reverse corticosteroid-induced protein catabolism in piglets. One is that IGF-I does not mediate all actions of GH. Assuming that GH reverses corticosteroid-induced protein catabolism, as has been shown in human adults(8) and in rats(7, 21), GH could mediate this reversal via an IGF-I independent mechanism(22), or by stimulating paracrine secretion of IGF-I(23), or by modifying IGF-I action through effects on IGF binding protein production(24). None of these mechanisms of GH action are reproduced when IGF-I is infused(22, 24). Another possible explanation is that the GH/IGF-I axis may not yet be physiologically active in very young animals. The anabolic response to GH increases with age in growing pigs(25). Data are lacking on whether GH has any anabolic effect in piglets of the size and age used in our study. Further evidence for the age dependence of the activity of the GH/IGF-I axis is provided by the fact that the somatogenic GH receptor is absent in the ovine fetal liver and does not appear until after birth(26). In a recent study in small-for-date premature infants, GH failed to produce a protein anabolic effect(27). A third explanation for the lack of effect of IGF-I could be a specific disturbance of IGF-I action through DEX. In human volunteers, DEX decreases IGF-I bioactivity, even in the presence of increased immunoreactive IGF-I levels(28). In fasted lambs(9) and in calorically restricted human volunteers(29), IGF-I decreases leucine oxidation in a dose-dependent manner, suggesting IGF-I may decrease protein catabolism in catabolic states not involving corticosteroid treatment. The final explanation is that the dose of IGF-I administered in our study could have been insufficient to cause a protein anabolic effect. IGF-I has been shown to reduce whole body protein catabolism in DEX-treated rats(30–32). In these studies very high doses of IGF-I (690 μg/kg/h) were used to achieve an anabolic effect. At doses similar to those used in our study, no protein anabolic effect was observed. The only study that we are aware of addressing the role of IGF-I in corticosteroid-induced protein catabolism in humans(22) failed to show a protein anabolic effect of IGF-I. However, a low dose was used (5-10 μg/kg/h). In our study, IGF-I at a dose of 25 μg/kg/h decreased serum glucose levels to baseline values. In view of the risk of hypoglycemia at higher IGF-I doses(10, 33), we considered it inadvisable to increase the dose of IGF-I in our study.
Our study further shows that IGF-I attenuates corticosteroid-induced hyperglycemia. The corticosteroid DEX increased blood glucose levels nearly 2-fold over baseline values. After adding IGF-I to DEX, blood glucose values decreased to near baseline values. This is probably due to cross-reaction of IGF-I with the insulin receptor(22). However, the lowering of blood glucose levels alone, without beneficial effect of IGF-I on protein metabolism, would not warrant treatment with IGF-I.
We conclude that IGF-I does not reverse corticosteroid-induced protein catabolism in growing piglets. IGF-I attenuates corticosteroid-induced hyperglycemia. We suggest that IGF-I may not be of therapeutic value in corticosteroid-induced protein catabolism in pediatric patients.
Abbreviations
- DEX:
-
dexamethasone
- KIC:
-
2-ketoisocaproate
- MPE:
-
mol% excess
References
Loeb JN 1976 Corticosteroids and growth. N Engl J Med 295: 547–552.
Beaufrere B, Horber FF, Schwenk WF, Marsh HM, Matthews D, Gerich JE, Haymond MW 1989 Glucocorticosteroids increase leucine oxidation and impair leucine balance in humans. Am J Physiol 257:E712–E721.
Simmons PS, Miles JM, Gerich JE, Haymond MW 1984 Increased proteolysis-an effect of increases in plasma cortisol within the physiologic range. J Clin Invest 73: 412–420.
Goudoever JB van, Wattimena DWL, Carnielli VP, Sulkers EJ, Degenhart HJ, Sauer PJJ 1994 Effect of dexamethasone on protein metabolism in infants with bronchopulmonary dysplasia (BPD). J Pediatr 124: 112–118.
Williams AF, Jones M 1992 Dexamethasone increases plasma amino acid concentrations in bronchopulmonary dysplasia. Arch Dis Child 67: 5–9.
Brownlee KG, Ng PC, Henderson MJ, Smith M, Green JH, Dear PRF 1992 Catabolic effect of dexamethasone in the preterm baby. Arch Dis Child 67: 1–4.
Selye H 1952 Prevention of cortisone overdosage effects with the somatotrophic hormone (STH). Am J Physiol 171: 381–384.
Horber FF, Haymond MW 1990 Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 86: 265–272.
Douglas RG, Gluckman PD, Ball K, Breier B, Shaw JHF 1991 The effects of infusion of insulin-like growth factor (IGF) I, IGF-II, and insulin on glucose and protein metabolism in fasted lambs. J Clin Invest 88: 614–622.
Turkalj I, Keller U, Ninnis R, Vosmeer S, Stauffacher W 1992 Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man. J Clin Endocrinol Metab 75: 1186–1191.
Tavakkol A, Simmen FA, Simmen RC 1988 Porcine insulin-like growth factor-I (pIGF-I): complementary deoxyribonucleic acid cloning and uterine expression of messenger ribonucleic acid encoding evolutionarily conserved IGF-I peptides. Mol Endocrinol 2: 674–681.
Schwander JC, Hauri C, Zapf J, Froesch ER 1983 Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology 113: 297–305.
Guler HP, Zapf J, Froesch ER 1987 Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317: 137–140.
Somers CJ, Wilson P, Ahern CP, McLoughlin JV 1977 Energy phosphate turnover and glycolysis in skeletal muscle of the Pietrain pig: the effects of premedication with azaperone and pentobarbitone anaesthesia. J Comp Pathol 87: 177–183.
Dundee JW, Haslett WHK 1970 The benzodiazepines: a review of their actions and uses relative to anesthetic practice. Br J Anaesth 42: 217–224.
Goudoever JB van, Sulkers EJ, Chapman TE, Carnielli VP, Efstatopoulos T, Degenhart HJ, Sauer PJJ 1993 Glucose kinetics and glucoregulatory hormone levels in ventilated preterm infants on the first day of life. Pediatr Res 33: 583–589.
Denne SC, Kalhan SC 1986 Glucose carbon recycling and oxidation in human newborns. Am J Physiol 251:E71–E77.
Matthews DE, Schwartz HP, Yang RD, Motil KJ, Young VR, Bier DM 1982 Relationship of plasma leucine and -ketoisocaproate during L-[1-13C]leucine infusion in man: a method for measuring human intracellular leucine tracer enrichment. Metabolism 31: 1105–1112.
Jansen J, Van Buul-Offers SC, Hoogerbrugge CM, Van den Brande JL 1990 Effects of a single cleavage in insulin-like carrier proteins and antibodies. Biochem J 266: 513–520.
Daughaday WH, Mariz IK, Blethen SL 1980 Inhibition of access of bound somatomedin to membrane receptors and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. J Clin Endocrinol Metab 51: 781–788.
Kovacs G, Fine RN, Worgall S, Schaefer F, Hunziker EB, Skottner-Lindun A, Mehls O 1991 Growth hormone prevents steroid-induced growth depression in health and uremia. Kidney Int 40: 1032–1040.
Mauras N, Horber FF, Haymond MW 1992 Low dose recombinant human insulin-like growth factor-I fails to affect protein anabolism but inhibits islet cell secretion in humans. J Clin Endocrinol Metab 75: 1192–1197.
D'Ercole AJ, Stiles AD, Underwood LE 1984 Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 81: 935–939.
Miell JP, Taylor AM, Jones J, Buchanan CR, Rennie J, Sherwood R, Leicester R, Ross RJM 1992 Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery. Clin Endocrinol 37: 542–551.
Kanis E, Nieuwhof GJ, de Greef KH, van der Hel W, Verstegen MWA, Huisman J, van der Wal P 1990 Effect of recombinant porcine somatotropin on growth and carcass quality in growing pigs: interactions with genotype, gender and slaughter weight. J Anim Sci 68: 1193–1200.
Gluckman PD, Butler JH, Elliott TB 1983 The ontogeny of somatotropic binding sites in ovine hepatic membranes. Endocrinology 112: 1607–1612.
van Toledo-Eppinga L, Kulik W, Houdijk MC, Jakobs C, Delemarre-Vande Waal HA, Lafeber HN 1995 Whole body protein turnover and energy expenditure in intrauterine growth retarded (IUGR) preterm infants during recombinant human growth hormone (rhGH) treatment. Pediatr Res 37: 322A
Miell JP, Taylor AM, Jones J, Holly JMP, Gaillard RC, Pralong FP, Ross RJM, Blum WF 1993 The effects of dexamethasone on immunoreactive and bioactive insulin-like growth factors (IGFs) and IGF-binding proteins in normal male volunteers. J Endocrinol 136: 525–533.
Clemmons DR, Smith-Banks A, Underwood LE 1992 Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans. J Clin Endocrinol Metab 75: 234–238.
Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC, Ballard FJ 1992 Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone treated rats. Biochem J 282: 91–97.
Yang H, Grahn M, Schalch DS, Ney DM 1994 Anabolic effects of IGF-I coinfused with total parenteral nutrition in dexamethasone-treated rats. Am J Physiol 266:E690–E698.
Read LC, Tomas FM, Howarth GS, Martin AA, Edson KJ, Gillespie CM, Owens PC, Ballard FJ 1992 Insulin-like growth factor-I and its N-terminal modified analogues induce marked gut growth in dexamethasone-treated rats. J Endocrinol 133: 421–431.
Elahi D, McAloon-Dyke M, Fukagawa NK, Sclater AL, Wong GA, Shannon RP, Minakeer KL, Miles JM, Rubenstein AH, Vandepol CJ, Guler HP, Good WR, Seaman JJ, Wolfe RR 1993 Effect of recombinant human IGF-I on glucose and leucine kinetics in men. Am J Physiol 265:E8310–E838.
Acknowledgements
The authors thank A. Heikamp for his expert assistance in performing the experiments, H. Elzinga for performing the isotope ratio/mass spectrometry measurements, J. v. Dooren for the determination of IGF-I, and M. Jansen and R. Baarsma for reviewing the manuscript. We also thank Genentech Co. for the generous gift of IGF-I.
Author information
Authors and Affiliations
Additional information
Supported by grant He2195/1-2 from the Deutsche Forschungsgemeinschaft (to G.H.). The project was funded by Klinisch VoedingsOnderzoek Groningen.
Rights and permissions
About this article
Cite this article
Hellstern, G., Reijngoud, DJ., Stellaard, F. et al. Insulin-Like Growth Factor-I Fails to Reverse Corticosteroid-Induced Protein Catabolism in Growing Piglets. Pediatr Res 39, 421–426 (1996). https://doi.org/10.1203/00006450-199603000-00008
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-199603000-00008